Royal Bank Of Canada downgraded shares of Hannover Ruck (OTCMKTS:HVRRY – Free Report) from a moderate buy rating to a hold rating in a research report released on Monday,Zacks.com reports.
Several other equities analysts have also weighed in on HVRRY. Zacks Research upgraded shares of Hannover Ruck from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 1st. UBS Group upgraded shares of Hannover Ruck from a “hold” rating to a “strong-buy” rating in a report on Friday, September 12th. Three analysts have rated the stock with a Strong Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy”.
View Our Latest Stock Analysis on Hannover Ruck
Hannover Ruck Trading Down 1.7%
Hannover Ruck (OTCMKTS:HVRRY – Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The financial services provider reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.26. Hannover Ruck had a net margin of 9.33% and a return on equity of 19.77%. The business had revenue of $7.96 billion for the quarter, compared to analyst estimates of $7.34 billion. On average, analysts predict that Hannover Ruck will post 3.42 EPS for the current year.
About Hannover Ruck
Hannover Rück SE, together with its subsidiaries, provides reinsurance products and services in Germany, the United Kingdom, France, Europe, the United States, Asia, Australia, Africa, and internationally. It operates through Property & Casualty Reinsurance; and Life & Health Reinsurance segments.
Further Reading
- Five stocks we like better than Hannover Ruck
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Hannover Ruck Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hannover Ruck and related companies with MarketBeat.com's FREE daily email newsletter.